Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Alba Rodríguez-Meira(Broad Institute), Ruggiero Norfo(University of Modena and Reggio Emilia), Sean Wen(University of Oxford), Agathe L. Chédeville(Inserm), Haseeb Rahman(University of Oxford), Jennifer O’Sullivan(University of Oxford), Guanlin Wang(University of Oxford), Eleni Louka(University of Oxford), Warren W. Kretzschmar(Karolinska University Hospital), Aimee Paterson(University of Oxford), Charlotte Brierley(Memorial Sloan Kettering Cancer Center), Jean‐Edouard Martin(Inserm), Caroline Demeule(CHU Dijon Bourgogne), Matthew Bashton(Northumbria University), Nikolaos Sousos(University of Oxford), Daniela Moralli(Centre for Human Genetics), Lamia Subha Meem(Centre for Human Genetics), Joana Carrelha(University of Oxford), Bishan Wu(University of Oxford), Angela Hamblin(University of Oxford), Hélène Guermouche(Inserm), Florence Pasquier(Inserm), Christophe Marzac(Inserm), François Girodon(Inserm), William Vainchenker(Inserm), Mark W. Drummond(Beatson West of Scotland Cancer Centre), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), J. Ross Chapman(University of Oxford), Isabelle Plo(Inserm), Sten Eirik W. Jacobsen(Karolinska University Hospital), Bethan Psaila(University of Oxford), Supat Thongjuea(University of Oxford), Iléana Antony‐Debré(Inserm), Adam J. Mead(University of Oxford)
Nature Genetics
September 1, 2023
Cited by 142Open Access
Full Text

Abstract

Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC clones at transformation, with a leukemia stem cell transcriptional signature strongly predictive of adverse outcomes in independent cohorts, across both TP53-mutant and wild-type (WT) AML. Through analysis of serial samples, antecedent TP53-heterozygous clones and in vivo perturbations, we demonstrate a hitherto unrecognized effect of chronic inflammation, which suppressed TP53 WT HSPCs while enhancing the fitness advantage of TP53-mutant cells and promoted genetic evolution. Our findings will facilitate the development of risk-stratification, early detection and treatment strategies for TP53-mutant leukemia, and are of broad relevance to other cancer types.


Related Papers